Published: Jeffrey Cummings

Dr. Jeffrey Cummings (Brain Health) recently published an article, “The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs," in the Journal of Prevention of Alzheimer’s Disease. The somewhat provocative findings note that despite the trend toward prevention trials becoming more likely (in part because trials in later stages of the disease have failed) they lack many of the essential aspects of successful clinical trials including a well defined target, enough decline in a placebo group, biomarkers to predict a clinical effect, and an interested market if the therapeutic agent works. Cummings concludes, "trials in patients with symptoms have a better chance of success in drug development trials than prevention trials." 

People in the News

People | December 3, 2021
An immigrant herself, Aziza Dhalai says she remembers how scary it can be to arrive in a new country.
People | November 30, 2021
Former flight attendant Ben Jantzen on being a nontraditional student and discovering a new career in college.
A woman leans on a cubicle wall
People | November 29, 2021
The Cannon Survey Center's data and operations manager grew up rural – very rural.